UTHR · Annual Report (Form 10-K) · Filed February 25, 2026

United Therapeutics Corp — 10-K exhibit

uthrexh23112312025.htm

United Therapeutics Corp on Boardroom Alpha

Document

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:


(1)						Registration Statement (Form S-4 No. 333-173857) pertaining to United Therapeutics Corporation common stock,

(2)						Registration Statement (Form S-8 No. 333-182851) pertaining to the United Therapeutics Corporation Employee Stock Purchase Plan,

(3)						Registration Statements (Form S-8 No. 333-205309, Form S-8 No. 333-225942, Form S-8 No. 333-232906, Form S-8 No. 333-240156, Form S-8 No. 333-258434, Form S-8 No. 333-266478) pertaining to the United Therapeutics Corporation 2015 Stock Incentive Plan,

(4)						Registration Statement (Form S-8 No. 333-229992) pertaining to the United Therapeutics Corporation 2019 Inducement Stock Incentive Plan, and

(5)						Registration Statements (Form S-8 No. 333-273590, Form S-8 No. 333-281117, Form S-8 No. 333-289068) pertaining to the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan;

of our reports dated February 25, 2026, with respect to the consolidated financial statements and schedule of United Therapeutics Corporation and the effectiveness of internal control over financial reporting of United Therapeutics Corporation included in this Annual Report (Form 10-K) of United Therapeutics Corporation for the year ended December 31, 2025.

/s/ Ernst & Young LLP

Tysons, Virginia

February 25, 2026

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer